April 20 (Reuters) - AstraZeneca said on Monday its experimental treatment tozorakimab showed a "meaningful reduction" in ...

In the spring, patients with chronic obstructive pulmonary disease (COPD) may develop a common acute respiratory viral infection (ARVI) into a serious exacerbation. On April 20, Sergey Avdeev, MD, ...

A third consecutive phase III success for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) tozorakimab in chronic obstructive pulmonary ...

Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disorder characterised by persistent airflow limitation and chronic inflammation. Beyond its primary pulmonary manifestations, ...

While chronic obstructive pulmonary disease can make exercise more challenging, regular physical activity may actually improve your symptoms and make it easier to perform everyday tasks. In addition ...

November is National Chronic Obstructive Pulmonary Disease Awareness Month. It’s time to raise awareness about lung disease within our communities. By understanding the causes, reducing our risk ...

Respiratory medicine has increasingly recognized the critical influence of respiratory viral infections on the development and exacerbation of chronic ...

AstraZeneca (AZN) tozorakimab achieves primary endpoint in Phase III MIRANDA trial, reducing COPD exacerbations in smokers ...

Chronic obstructive pulmonary disease (COPD) remains a substantial contributor to morbidity and mortality in the United States with an estimated 3.8% age-adjusted prevalence and 141,733 COPD deaths ...

TARRYTOWN, N.Y. and PARIS, May 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 trial, AERIFY-1, evaluating the investigational use ...

Adding as little as 1,700 to 5,500 steps per day can offset the risk of a list of chronic diseases—including obesity, diabetes and sleep apnea—according to a new study from a corresponding author with ...